Epstein-Barr virus (EBV or HHV-4) belongs to the family of Herpesviridae and is known as the cause of infectious mononucleosis. Being able to establish a long-term, latent infection in human B cells, it is prevalent in the adult population (worldwide 90%).
EBV is associated with a range of human diseases and cancers:
- Hodgkin’s and Burkitt’s lymphoma
- Nasopharyngal carcinoma
- Main cause of post-transplant lymphoproliferative disease (PTLD) in immune suppressed transplant patients
- Increases the risk of certain autoimmune diseases, e.g. lupus erythematosus, rheumatoid arthritis and multiple sclerosis
- Plays a role in the development of chronic fatigue syndrome (CFS)
During latent infection EBV expresses a small number of genes (e.g. EBNA1 -3 and LMP1 -2). Three major types of latency can be differentiated by their distinct expression patterns and are associated with the various types of diseases and cancer. Both, humoral and cellular (mainly CTL) immune responses play a role in controlling the primary and the latent phases of EBV infection.
Cellular Immune Response Profiling
- Immune monitoring of high-risk patients
- Qualification of immunodominant antigens
- Validating clinical T-cell assays
PepMix™ Collection EBV
The PepMix™ Collection EBV provides peptide pools (2 aliquots each) of 13 immunodominant antigens in one plate for fast and economic immune response profiling.
EBV PepMix™ Peptide Pools
Individual peptide pools comprise overlapping peptide scans through single immunodominant antigens:
BARF1, BMLF1, BMRF1, BRLF1, BZLF1, EBNA-LP, EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, LMP1, LMP2, GP350/340
Tailored EBV PepMix™ Peptide Pools
Peptide Pools tailored for your specific needs!
- High-throughput T-cell epitope discovery
- Monitoring of cellular immune response
- Clinical trials
We are the experts for peptide synthesis with highest quality optimized for many applications. Our peptide synthesis service has a very high success rate (over 99%) as we optimize the appropriate peptide synthesis method for each peptide.
If you would like to order a quality peptide synthesis using regulated processes, choose JPT!
Humoral Immune Response Profiling
- Immune monitoring of humoral responses
- Profiling of EBV specific samples or antibodies
- Evaluation of co-infection
- Detection of epitopes and epitope spreading
Catalog RepliTope™ Peptide Microarrays
Ready-made peptide microarrays displaying overlapping peptides through single immunodominant antigens: BARF1, BMLF1, BMRF1, BRLF1, BZLF1, EBNA-LP, EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, LMP1, LMP2, GP350/340.
Catalog RepliTope™ Antigen Collection
The RepliTope™ Antigen Collection combines overlapping peptides for all the proteins above on one microarray for optimal coverage of the most important antigens in a single experiment.
> RepliTope™ Peptide Microarrays Product Page
Tailored PepStar™ Peptide Microarrays
You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored peptide microarray.
> PepStar™ Peptide Microarrays Product Page
Our tailored Peptide ELISA plates are offered as stand alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT’s peptide microarrays.
JPT’s Clinical Peptides product lines GxP and ISO Plus are produced in production environments that are regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development. Depending on the specifics of the immunotherapy concept to be applied, the resulting products have been shown to be applicable in clinical applications.
"Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay"
Cassaniti et al, Journal of Immunology Research (2019)
"Measurement of CD8.sup.+ and CD4.sup.+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs"
Dae-Hee Sohn et al, PLoS ONE (2019)
"T-Cell Responses Targeting HIV Nef Uniquely Correlate With Infected Cell Frequencies After Long-Term Antiretroviral Therapy"
Thomas et al, PLoS Pathogens (2019)
"PRAME Peptide‐Specific CD8+ T Cells Represent the Predominant Response Against Leukemia‐Associated Antigens (LAAs) in Healthy Individuals"
Matko et al, European Journal of Immunology (2018)
"Dynamics of Virus‐Specific T Cell Immunity in Pediatric Liver Transplant Recipients"
Arasaratnam et al, American Journal of Transplantation (2018)
"Epstein-Barr Virus (EBV)-derived BARF1 Encodes CD4-and CD8-restricted Epitopes as Targets for T-cell Immunotherapy"
Kalra et al, Cytotherapy (2018)
"My group is developing therapeutic strategies for using in vitro expanded virus-specific T cells (VSTs) for the treatment of viral infections in immunocompromised patients. We recently demonstrated the feasibility and clinical benefit associated with the infusion of rapidly generated single-culture VSTs, manufactured using JPT's GxP PepMix™ peptide pools covering 12 immunogenic antigens from five viruses (EBV, AdV, CMV, BK, and HHV6). When administered to 11 allogeneic stem cell transplant recipients, 8 of whom had up to four active infections, these VSTs produced an overall 94% response rate."
Ann Leen, PhD, Baylor College of Medicine, Houston, TX, USA
"The main focus of my research group at the Charité in Berlin is the development of novel immunotherapeutic approaches against cancer and infectious diseases. For reliable monitoring of tumor and virus specific T-cell responses we have a permanent need for peptides and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard which continuously works on improving it's peptide based services."
Prof. Dr. Carmen Scheibenbogen, Charité Berlin, Germany
Peptide-stimulated Expansion of Virus-specific T cells for Preventative Treatment after Allogeneic Stem Cell Transplantation
Gary et. al, Apllication Note (2015)
Multiple Sclerosis and Epstein‐Barr Virus Infection - An Epitope Mapping Study
Reimer et al., Application Note (2014)
BioTides™ as High Throughput Screening Tool for the Identification of Antibody Binding Sites
Kuehne et al., Application Note (2012)
A Modular Approach for Epitope Discovery and High-Resolution Profiling of Humoral Immune Responses
Pawlowski et al., Application Note (2013)
PepMix™ Peptide Pools for Clinical Applications
Keirnan et al., Application Note (2012)
More application notes